Table 2.
Price paid by consumers at private-sector retail pharmacies for each product version of surveyed medicines and their MPRs
| Anti-neoplastic essential medicines | Product type | Median price (INR) | Minimum price (INR) | Maximum price (INR) | MPR |
| Asparaginase, powder inj, 10 000 IU in vial | OB | – | – | – | – |
| MSG | 1500 | 1300 | 1564 | 0.45 | |
| LPG | 1500 | 952 | 1564 | 0.45 | |
| Bleomycin, powder inj, 15 mg | OB | – | – | – | – |
| MSG | 540 | 364 | 650 | 0.71 | |
| LPG | 530 | 364 | 595 | 0.69 | |
| Carboplatin, inj, 150 mg/15 mL | OB | – | – | – | – |
| MSG | 730 | 600 | 850 | 0.78 | |
| LPG | 680 | 600 | 850 | 0.72 | |
| Carboplatin, inj, 450 mg/45 mL | OB | – | – | – | – |
| MSG | 2000 | 1650 | 2466 | 0.92 | |
| LPG | 2000 | 1650 | 2466 | 0.92 | |
| Cisplatin, inj, 50 mg/50 mL | OB | – | – | – | – |
| MSG | 302 | 280 | 336 | 0.80 | |
| LPG | 302 | 250 | 336 | 0.80 | |
| Cyclophosphamide, powder inj, 500 mg in vial | OB | 76 | 60 | 76 | 0.15 |
| MSG | 65 | 40 | 76 | 0.13 | |
| LPG | 65 | 40 | 76 | 0.13 | |
| Cytarabine, powder inj, 100 mg in vial | OB | 200 | 190 | 200 | 1.02 |
| MSG | 150 | 100 | 200 | 0.77 | |
| LPG | 150 | 100 | 200 | 0.77 | |
| Dacarbazine, powder inj, 100 mg in vial | OB | – | – | – | – |
| MSG | 250 | 250 | 250 | NA | |
| LPG | 250 | 250 | 250 | NA | |
| Dactinomycin, powder inj, 500 µg in vial | OB | – | – | – | – |
| MSG | 442 | 350 | 445 | 0.81 | |
| LPG | 442 | 350 | 445 | 0.81 | |
| Doxorubicin, powder inj, 10 mg | OB | 158 | 140 | 175 | 1.18 |
| MSG | 148 | 120 | 180 | 1.10 | |
| LPG | 148 | 120 | 180 | 1.10 | |
| Doxorubicin, powder inj, 50 mg | OB | 750 | 700 | 1276 | 1.64 |
| MSG | 510 | 300 | 1276 | 1.12 | |
| LPG | 510 | 300 | 1276 | 1.12 | |
| Etoposide, inj, 100 mg/5 mL | OB | – | – | – | – |
| MSG | 173 | 150 | 200 | 1.40 | |
| LPG | 173 | 140 | 200 | 1.40 | |
| Ifosfamide, powder inj, 2 g vial | OB | 950 | 350 | 1131 | 0.31 |
| MSG | 781 | 350 | 1015 | 0.26 | |
| LPG | 781 | 350 | 1015 | 0.26 | |
| Ifosfamide, powder inj, 1 g | OB | – | – | – | – |
| MSG | 450 | 300 | 565 | 0.66 | |
| LPG | 450 | 300 | 565 | 0.66 | |
| Mercaptopurine, tab, 50 mg | OB | – | – | – | – |
| MSG | 69 | 55 | 80 | 0.05 | |
| LPG | 69 | 55 | 80 | 0.05 | |
| Methotrexate, powder inj, 50 mg in vial | OB | – | – | – | – |
| MSG | 92 | 50 | 92 | NA | |
| LPG | 92 | 40 | 92 | NA | |
| Methotrexate, tab, 2.5 mg | OB | – | – | – | – |
| MSG | 45 | 40 | 55 | 0.45 | |
| LPG | 45 | 40 | 55 | 0.45 | |
| Paclitaxel, powder inj, 6 mg/mL | OB | – | – | – | – |
| MSG | 900 | 450 | 910 | 0.04 | |
| LPG | 885 | 450 | 910 | 0.04 | |
| Prednisolone, oral liquid, 5 mg/mL | OB | – | – | – | – |
| MSG | 20 | 20 | 40 | NA | |
| LPG | 20 | 20 | 40 | NA | |
| Prednisolone, tab, 5 mg | OB | – | – | – | – |
| MSG | 6 | 5 | 6 | 0.86 | |
| LPG | 6 | 5 | 6 | 0.82 | |
| Thioguanine, solid oral dosage form, 40 mg | OB | – | – | – | – |
| MSG | 270 | 148 | 300 | 0.06 | |
| LPG | 270 | 148 | 300 | 0.06 | |
| Vinblastine, powder inj, 10 mg (sulfate) in vial | OB | – | – | – | – |
| MSG | 200 | 160 | 282 | 1.24 | |
| LPG | 200 | 160 | 282 | 1.24 | |
| Vincristine, powder inj, 1 mg | OB | – | – | – | – |
| MSG | 48 | 40 | 75 | 0.23 | |
| LPG | 48 | 35 | 75 | 0.23 | |
| Median MPR of MSG | 0.74 | ||||
| Median MPR of LPG | 0.71 | ||||
| Median MPR of OB | 1.00 | ||||
| Non-canceressential medicines* | |||||
| Amoxicillin 250 mg tab/cap | OB | – | – | – | – |
| MSG | 22 | 19 | 27 | 2.22 | |
| LPG | 22 | 9 | 27 | 2.22 | |
| Ciprofloxacin 500 mg, cap/tab | OB | – | – | – | – |
| MSG | 37 | 30 | 49 | 1.57 | |
| LPG | 37 | 30 | 49 | 1.57 | |
| Metformin 500 mg cap/tab | OB | – | – | – | – |
| MSG | 15 | 10 | 19 | 1.61 | |
| LPG | 15 | 9 | 15 | 1.59 | |
| Omeprazole 20 mg, cap/tab | OB | – | – | – | – |
| MSG | 25 | 22 | 36 | 2.85 | |
| LPG | 25 | 20 | 33 | 2.83 | |
| Median MPR of MSG | 1.92 | ||||
| Median MPR of LPG | 1.90 |
*Median MPR for OB was not calculated as OBs were unavailable.
LPG, lowest-priced generic; MPR, median price ratio; MSG, most-sold generic; OB, originator brand.